On March 1, the U.S. Food and Drug Administration (FDA) released a safety communication consisting of updated commendations concerning drug-drug interactions between statins and protease inhibitors. Taking the two types of drugs can increase the blood level of the statin and increase the risk for myopathy, including rhabdomyolysis. Read more.
FDA issues safety communication on interactions between statins and protease inhibitors
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
